Although, preclinical studies found that targeting TDO significantly decreased the incidence of cancer progression and restored anticancer immunity [73,74,75,76], inhibition of IDO1 may enhance TDO expression and activity (Figure 2). This evidence concerns the gene TDO2 and cancer.